Vaccine effectiveness against COVID-19 hospitalization in adults in France: A test negative case control study

被引：6
|
作者：
Ngyen, Liem Binh Luong [1 ]
Bauer, Rebecca [2 ]
Lesieur, Zineb [3 ]
Galtier, Florence [4 ]
Duval, Xavier [5 ]
Vanhems, Philippe [6 ]
Laine, Fabrice [7 ]
Tattevin, Pierre [8 ,9 ]
Durier, Christine [2 ]
Launay, Odile [1 ,3 ]
机构：
[1] Hop Cochin, AP HP, INSERM, CIC 1417, Paris, France
[2] INSERM, US19, Villejuif, France
[3] F CRIN I REIVAC, INSERM, Paris, France
[4] CHU Montpellier, St Eloi Hosp, INSERM, CIC 1411, Montpellier, France
[5] Hop Bichat Claude Bernard, AP HP, INSERM, CIC 1425, Paris, France
[6] Hosp Civils Lyon, Serv Hyg Epidemiol Infectiovigilance & Prevent, Lyon, France
[7] CHU Rennes, Inserm CIC 1414, Rennes, France
[8] CHU Rennes, Hop Pontchaillou, Serv Malad Infect, Rennes, France
[9] CHU Rennes, Hop Pontchaillou, Serv Reanimat Med, Rennes, France
来源：
INFECTIOUS DISEASES NOW | 2022年 / 52卷 / 01期
关键词：
Alpha variant; COVID-19; France; Vaccine; Vaccine effectiveness;
D O I：
10.1016/j.idnow.2021.12.002
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
Background: Measuring vaccine effectiveness (VE) using real-life data is critical to confirm the effectiveness of licensed vaccine, which could strengthen vaccination adherence. Methods: We measured VE against adult COVID-19 hospitalization in five hospitals in France using a test negative design. We compared the odds of vaccinated patients hospitalized with COVID-19 with the odds of vaccinated patients hospitalized for the same symptoms with a negative test. Results: A total of 853 patients (463 cases and 390 controls) were included, with a total of 170 patients vaccinated (104 with one dose, 65 with two doses, and one with three doses). There were four cases of breakthrough infections, all in immunocompromised patients. The VE was 84.0% (CI0.95 = [72.6; 90.6]) for one dose and 96.2% (CI0.95 = [86.8; 98.9]) for two doses. Conclusion: Our results confirm the high VE of COVID-19 vaccine in France to prevent hospitalizations due to the alpha variant.
引用
收藏
页码：40 / 43
页数：4
相关论文
共 50 条
  • [31] Surveillance of COVID-19 vaccine effectiveness: a real-time case-control study in southern Sweden
    Bjork, Jonas
    Bonander, Carl
    Moghaddassi, Mahnaz
    Rasmussen, Magnus
    Malmqvist, Ulf
    Kahn, Fredrik
    Inghammar, Malin
    EPIDEMIOLOGY AND INFECTION, 2022, 150
  • [32] Comparing real-life effectiveness of various COVID-19 vaccine regimens during the delta variant-dominant pandemic: a test-negative case-control study
    Sritipsukho, Paskorn
    Khawcharoenporn, Thana
    Siribumrungwong, Boonying
    Damronglerd, Pansachee
    Suwantarat, Nuntra
    Satdhabudha, Araya
    Chaiyakulsil, Chanapai
    Sinlapamongkolkul, Phakatip
    Tangsathapornpong, Auchara
    Bunjoungmanee, Pornumpa
    Nanthapisal, Sira
    Tanprasertkul, Chamnan
    Sritipsukho, Naiyana
    Mingmalairak, Chatchai
    Apisarnthanarak, Anucha
    Tantiyavarong, Pichaya
    EMERGING MICROBES & INFECTIONS, 2022, 11 (01) : 585 - 592
  • [33] COVID-19 vaccine effectiveness by HIV status and history of injection drug use: a test-negative analysis
    Puyat, Joseph H.
    Wilton, James
    Fowokan, Adeleke
    Janjua, Naveed Zafar
    Wong, Jason
    Grennan, Troy
    Chambers, Catharine
    Kroch, Abigail
    Costiniuk, Cecilia T.
    Cooper, Curtis L.
    Lauscher, Darren
    Strong, Monte
    Burchell, Ann N.
    Anis, Aslam
    Samji, Hasina
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2023, 26 (10)
  • [34] Estimating the population effectiveness of interventions against COVID-19 in France: A modelling study
    Ganser, Iris
    Buckeridge, David L.
    Heffernan, Jane
    Prague, Melanie
    Thiebaut, Rodolphe
    EPIDEMICS, 2024, 46
  • [35] Effectiveness of BNT162b2 Vaccine for Preventing COVID-19-Related Hospitalizations: A Test-Negative Case-Control Study
    Keane, Amy
    Tippett, Ashley
    Taylor, Elizabeth Grace
    Reese, Olivia
    Salazar, Luis
    De Castro, Khalel
    Choi, Chris
    Ciric, Caroline
    Taylor, Meg
    Mitchell, Anna
    Gibson, Theda
    Puzniak, Laura
    Hubler, Robin
    Valluri, Srinivas Rao
    Wiemken, Timothy L.
    Lopman, Ben A.
    Kamidani, Satoshi
    Anderson, Larry J.
    Mclaughlin, John M.
    Rostad, Christina A.
    Anderson, Evan J.
    VACCINES, 2024, 12 (06)
  • [36] Effectiveness of autumn 2023 COVID-19 vaccination and residual protection of prior doses against hospitalisation in England, estimated using a test-negative case-control study
    Kirsebom, Freja C. M.
    Stowe, Julia
    Bernal, Jamie Lopez
    Allen, Alex
    Andrews, Nick
    JOURNAL OF INFECTION, 2024, 89 (01)
  • [37] Vaccine effectiveness of ChAdOx1 nCoV-19 against COVID-19 in a socially vulnerable community in Rio de Janeiro, Brazil: a test-negative design study
    Ranzani, Otavio T.
    Silva, Amanda A. B.
    Peres, Igor T.
    Antunes, Bianca B. P.
    Gonzaga-da-Silva, Thiago W.
    Soranz, Daniel R.
    Cerbino-Neto, Jose
    Hamacher, Silvio
    Bozza, Fernando A.
    CLINICAL MICROBIOLOGY AND INFECTION, 2022, 28 (05) : 736.e1 - 736.e4
  • [38] Vaccine effectiveness and duration of protection of COVID-19 mRNA vaccines against Delta and Omicron BA.1 symptomatic and severe COVID-19 outcomes in adults aged 50 years and over in France
    Tchuem, Cynthia Raissa Tamandjou
    Auvigne, Vincent
    Vaux, Sophie
    Montagnat, Charline
    Paireau, Juliette
    Besnard, Stephanie Monnier
    Gabet, Amelie
    Benhajkassen, Nabil
    Le Strat, Yann
    Chatelet, Isabelle Parent Du
    Levy-Bruhl, Daniel
    VACCINE, 2023, 41 (13) : 2280 - 2288
  • [39] COVID-19 vaccine effectiveness against severe COVID-19 requiring oxygen therapy, invasive mechanical ventilation, and death in Japan: A multicenter case-control study (MOTIVATE study)
    Arashiro, Takeshi
    Miwa, Maki
    Nakagawa, Hidenori
    Takamatsu, Junpei
    Oba, Kunihiro
    Fujimi, Satoshi
    Kikuchi, Hitoshi
    Iwasawa, Takamasa
    Kanbe, Fumiko
    Oyama, Keisuke
    Kanai, Masayuki
    Ogata, Yoshitaka
    Asakura, Takanori
    Asami, Takahiro
    Mizuno, Keiko
    Sugita, Manabu
    Jinta, Torahiko
    Nishida, Yusuke
    Kato, Hideaki
    Atagi, Kazuaki
    Higaki, Taiki
    Nakano, Yoshio
    Tsutsumi, Takeya
    Doi, Kent
    Okugawa, Shu
    Ueda, Akihiro
    Nakamura, Akira
    Yoshida, Toru
    Shimada-Sammori, Kaoru
    Shimizu, Keiki
    Fujita, Yasuo
    Okochi, Yasumi
    Tochitani, Kentaro
    Nakanishi, Asuka
    Rinka, Hiroshi
    Taniyama, Daisuke
    Yamaguchi, Asase
    Uchikura, Toshio
    Matsunaga, Maiko
    Aono, Hiromi
    Hamaguchi, Masanari
    Motoda, Kentaro
    Nakayama, Sohei
    Yamamoto, Kei
    Oka, Hideaki
    Tanaka, Katsushi
    Inoue, Takeshi
    Kobayashi, Mieko
    Fujitani, Shigeki
    Tsukahara, Maki
    VACCINE, 2024, 42 (03) : 677 - 688
  • [40] Intention to participate in a COVID-19 vaccine clinical trial and to get vaccinated against COVID-19 in France during the pandemic
    Detoc, Maelle
    Bruel, Sebastien
    Frappe, Paul
    Tardy, Bernard
    Botelho-Nevers, Elisabeth
    Gagneux-Brunon, Amandine
    VACCINE, 2020, 38 (45) : 7002 - 7006
12345